Results 161 to 170 of about 145,113 (281)

Integrated transcriptomic, protein, and MicroRNA profiling reveals a conserved pyroptosis-related molecular signature across breast cancer subtypes. [PDF]

Front Mol Biosci
Panfil A, Sirek T, Sirek A, Zmarzły N, Wróbel M, Wróbel Z, Boroń K, Boroń D, Ossowski P, Stefaniak M, Ordon P, Wyrobiec G, Wyrobiec P, Grabarek BO.   +13 more
europepmc   +1 more source

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

Isolated signals in BCL2, MYC, BCL6, and DDIT3 FISH: implications for genetic alterations and protein dysregulation. [PDF]

Pathol Oncol Res
Wei Z, Chen Q, Feng Z, Tang F.
europepmc   +1 more source

BCL2 wt Allele [PDF]

, 2020
openaire   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Sesamin Protects Against Polystyrene Microplastics-Induced Lung Injury via Attenuating Bcl2-Mediated Apoptosis. [PDF]

Antioxidants (Basel)
Zhang Y, Zhang Z, Pei H, Zhang C, Zhang X, Qiao S, Zhu S, Wang Z, Ren J, Ma Y.   +9 more
europepmc   +1 more source

Anti-BCL2 Antibody [PDF]

, 2020
openaire   +1 more source

FB23‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF/ERCC1 Complex

Cancer Science, EarlyView.
FB23‐2 potentiates cisplatin's antitumor efficacy in head and neck squamous cell carcinoma by disrupting XPF/ERCC1 complex assembly and nuclear translocation, thereby suppressing DNA damage repair machinery and amplifying platinum‐induced tumor cell death.
Yaoqi Jiang, Hongshi Cai, Yue Zhu, Jianfeng Liang, Hongyu Li, Fan Song, Ziyi Wang, Jinsong Hou   +7 more
wiley   +1 more source

Protective effect of Lactococcus lactis NZ9000 secreting Bcl2 against Trichinella spiralis infection in mice. [PDF]

BMC Vet Res
Wang R, Liu S, Zhang H, Feng D, Lin Y, Li S, Shen J, Wen B, Sun H, Li M, Wang Q, Wei L, Ma Y, Lu Y, Wang L.   +14 more
europepmc   +1 more source

BCL2 Gene Mutation [PDF]

, 2020
openaire   +1 more source